Jazz Pharmaceuticals

JAZZ · NASDAQ🇮🇪

Overview

Earnings Dividends Seasonality Metrics

Reported earnings about 1 month ago

Total Revenue

$1.2B

Previous year: $1.09B

Non-GAAP Gross Margin

90.6%

Previous year: 91.6%

-1.1%

GAAP SG&A % of Revenue

Previous year: $1.09B

-4.0%

Cash and Equivalents

$1.39B

Previous year: $2.41B

Loading...

Jazz Pharmaceuticals

Unlock previous datapoints

Upgrade

Jazz Pharmaceuticals

Unlock previous datapoints

Upgrade

Jazz Pharmaceuticals Revenue by Segment

Revenue by Segment

Xywav Revenue

CapyFin.com

Xyrem Revenue

CapyFin.com

Epidiolex/Epidyolex Revenue

CapyFin.com

Sativex Revenue

CapyFin.com

Rylaze/Enrylaze Revenue

CapyFin.com

Zepzelca Revenue

CapyFin.com

Defitelio/defibrotide Revenue

CapyFin.com

Vyxeos Revenue

CapyFin.com

Modeyso Revenue

CapyFin.com

Ziihera Revenue

CapyFin.com

Royalties & Contract Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$11.2B

P/E Ratio

27.37

Sector

N/A

Industry

N/A

52-Week High

$197

52-Week Low

$97.7

GAAP Gross Margin

86.4%

Non-GAAP Gross Margin

90.6%

GAAP SG&A % of Revenue

33.9%

GAAP R&D % of Revenue

17.9%

GAAP Effective Tax Rate

2.4%

Products

Get in Touch

Resources

Jazz Pharmaceuticals

Jazz Pharmaceuticals

Jazz Pharmaceuticals

Jazz Pharmaceuticals Revenue by Segment

Revenue by Segment

Xywav Revenue

Xyrem Revenue

Epidiolex/Epidyolex Revenue

Sativex Revenue

Rylaze/Enrylaze Revenue

Zepzelca Revenue

Defitelio/defibrotide Revenue

Vyxeos Revenue

Modeyso Revenue

Ziihera Revenue

Royalties & Contract Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics